In late February the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences (NIGMS) co-issued a NOSI (Notice of Special Interest - NOT-AI-20-030) informing investigators of the urgent need for research on the 2019 novel Coronavirus (2019-nCoV).  The NOSI was issued so investigators can write competitive revisions to existing NIH grants and cooperative agreements where the original intent naturally extends to research in 2019-nCoV.





NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.

NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.

Applications in response to this NOSI must be submitted using the following targeted funding opportunity:

• PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant. Further details can be found here: https://www.niaid.nih.gov/grants-contracts/urgent-award-mechanism..
• The funding instrument, or activity code, will be the same as the parent award.
• Please note: NOT-AI-20-030 is specific for PA-18-935. NIH grantees seeking additional funds for research responsive to the 2019-nCoV outbreak that falls within the scope of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements FOA (https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html).

Special conditions as far as page limits, time frame, budgets and more are in place. For more information or questions about this notice, please contact your pre-award analyst.